Exemestane Monotherapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Exemestane Monotherapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer | 3 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive, PR positive | Invasive Breast Carcinoma | Exemestane | |
| Sensitivity (+) | ER positive | Invasive Breast Carcinoma | Exemestane | |
| Sensitivity (+) | PR positive | Invasive Breast Carcinoma | Exemestane |